^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | RMC-4550 (PTPN11 inhibitor) + RM-029 (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
871 Combining KRASG12C(ON) inhibitor with SHP2 and/or immune checkpoint blockade to overcome adaptive resistance and enhance anti-tumour immunity in lung cancer
Published date:
11/04/2023
Excerpt:
In this study we use a novel, covalent tri-complex KRASG12C(ON) inhibitor, RM-029, which targets KRASG12C in the active state in combination with the SHP2 inhibitor RMC-4550 (both preclinical tool compounds), and studied their in vivo anti-tumor activity on transplantable KRAS-mutant lung cancer mouse models...In vitro, RM-029 exhibited higher potency for inhibition of cell viability than the KRASG12C(OFF) inhibitor MRTX849 in both human and murine NSCLC cell lines.
DOI:
http://dx.doi.org/10.1136/jitc-2023-SITC2023.0871
